Ocrelizumab biosimilar (Celltrion)

N/A

Report date: 2024/02/07 20:05:28

Base Information

Drug NameOcrelizumab biosimilar (Celltrion)
Drug Alias NameCT-P53
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAnti-CD20CD20-directed cytolytic effectsComplement dependent cytotoxicity (CDC) effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsMultiple Sclerosis, Relapsing-Remitting
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPoland
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Inc
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis, Relapsing-Remitting
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A